Ep. 138: “Cell-Based Therapies in Late-Stage Clinical Trial” Featuring Dr. Robert Mays
Dr. Robert Mays is the Co-founder and Vice President of Regenerative Medicine and Head of Neuroscience Programs at Athersys Inc. He focuses on Athersys’ proprietary stem cell product, MultiStem®, and its applications in regenerative medicine and drug discovery, with a specific focus on injuries and diseases affecting the central nervous system.
Resources and Links
New Drug Developed to Treat Heart Attack Damage – Using iPSC-derived cardiomyocytes, scientists have developed a new drug that minimizes cardiomyocyte death following a heart attack.
Enhancing iPSC Immune Compatibility – Researchers used CRISPR to make immunocompatible donor iPSCs that could increase iPSC-based regenerative medicine applications.
Kidney Organoids Created from Urine – Researchers have generated kidney tubular epithelial organoids from both kidney tissue and urine cells, which can be used for personalized disease modeling.
Modeling Developmental Disorder with Brain Organoids – Cerebral organoids were used to model the developmental disorder neuronal heterotopia, providing insight into the mechanisms causing impaired neuronal migration.
Cancer-Specific Inhibitor Identified – Researchers have identified a cancer-specific inhibitor that targets the metabolic needs of cancer cells.
Photo Reference: Courtesy of Dr. Robert Mays